Clinics in Montana
By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed. Last verified
What Montana law means for peptide clinics: who may prescribe, whether pharmacies may compound GLP-1 drugs (limited), how to check a clinic, and listings with their verification status.
Montana at a glance
- Pharmacy regulator
- Montana Board of Pharmacy (Department of Labor and Industry, Business Standards Division)
- 503A framework
- Follows the federal 503A framework
- Telehealth prescribing
- Regulatory: Telehealth allowed
- Asynchronous prescribing
- Regulatory: Async allowed
- Compounded GLP-1 access
- Regulatory: Compounded GLP-1 limited
Clinics serving Montana
No verified clinics serving Montana are listed yet. A provider appears here only after it passes the verification checklist, and those checks are still under way.
Looking for care now? Start with what the law allows where you live, then how a legitimate prescription works.
Run a pharmacy, clinic, or telehealth service? Apply for a listing.
Peptide access rules in Montana
Yes. A Montana resident can obtain FDA approved peptides such as semaglutide and tirzepatide from a Montana-licensed prescriber, including by telehealth, which Montana defines broadly (MCA 37-2-305) to include audio-only care, and a provider-patient relationship may be established through telemedicine (ARM 24.156.813) when the standard of care does not require an in-person visit. Fax, e-mail, or instant messaging used by itself does not count. A compounded peptide is available when it is eligible under federal 503A rules and dispensed by a pharmacy licensed by the Montana Board of Pharmacy; out-of-state mail order pharmacies must register under MCA 37-7-703 and name the pharmacist in charge of Montana dispensing. [1] [2] [3] [4] [5] [6] [7] [8] [10]
Compounded GLP-1 access in Montana
Rural Montana patients often rely on mail order; any out-of-state pharmacy mailing compounded GLP-1s into Montana must be registered as an out-of-state mail order pharmacy under MCA 37-7-703. [5] [11]
Research use only sellers in Montana
The Montana Food, Drug, and Cosmetic Act (MCA Title 50, chapter 31) prohibits selling adulterated or misbranded drugs, and MCA Title 37, chapter 7 restricts dispensing of prescription drugs to licensed pharmacies. [1] [5] [9] [12]
How to check a clinic in Montana
- Confirm the prescribing clinician's license with the Montana medical or nursing board.
- Ask which pharmacy compounds or dispenses the peptide and check it in the Montana Board of Pharmacy (Department of Labor and Industry, Business Standards Division) license lookup. [1] [5] [6] [7] [8] [10]
- Confirm the peptide can be lawfully compounded: check its status on the regulatory tracker or its peptide page before paying.
- Walk away from any seller that labels a peptide "research use only" or "not for human consumption". See the research use only section above for what that means in Montana. [1] [5] [9] [12]
Common questions in Montana
Can I get a GLP-1 prescription in Montana through telehealth?
Yes, from a Montana-licensed prescriber. MCA 37-2-305 authorizes telehealth, including audio-only care, and Board rule ARM 24.156.813 lets a relationship be established through telemedicine when the standard of care does not require an in-person visit. Fax, e-mail, or instant messaging used by itself does not count as telehealth or telemedicine. Semaglutide and tirzepatide are not controlled substances. [2] [3] [4]
Sources
- [1]Montana Board of Pharmacy
- [2]MCA 37-2-305, Telehealth services, rulemaking authority
- [3]MCA 37-3-102, Definitions (practice of medicine, store-and-forward technology, telemedicine)
- [4]ARM 24.156.813, Practice requirements for physicians and physician assistants using telemedicine (official site; rule text confirmed on the Cornell LII copy)
- [5]MCA 37-7-703, Out-of-state mail order pharmacy registration requirements
- [6]ARM 24.174.1001, Registration of out-of-state mail service pharmacies
- [7]ARM 24.174.841, Sterile products
- [8]Montana Board of Pharmacy, MAR Notice No. 2026-131, proposed amendment of ARM 24.174.841 and adoption of compounding rules
- [9]MCA Title 50, chapter 31, Food, drugs, and cosmetics
- [10]FDA: Section 503A of the Federal Food, Drug, and Cosmetic ActFDA
- [11]FDA: concerns with unapproved GLP-1 drugs used for weight loss, including shortage resolution and compounding grace periodsFDA
- [12]21 U.S.C. 331, Prohibited acts